In a recent study targeting age-related frailty, researchers tested a novel therapy using a single dose of mesenchymal stem cells derived from donated bone marrow. The trial included 148 walking adults aged 70 to 85, with 118 receiving varying doses of the laboratory-grown stem cells and 30 receiving a placebo. Because these specific stem cells lack the surface proteins that typically trigger immune rejection, participants did not need to take risky immunosuppressive medications. The results showed that nine months after the treatment, participants who received the highest dose of stem cells experienced about a 20% improvement in physical endurance, walking an average of 60 meters farther during a six-minute walk test compared to their pre-treatment baseline.
Paper · Nature · 2026Stem cells provide a potent treatment for frailtynature.comCholesterol as a master regulator of blood stem cells, driving inflammatory hematopoiesis
Review of preclinical evidence that high LDL pulls hematopoietic stem cells out of dormancy, causing proliferation, oxidative stress, telomere shortening, impaired repopulation and lasting epigenetic changes that program blood and immune cells toward chronic inflammation. This offers a molecular basis for residual inflammatory risk after cholesterol is treated.



